Lorlatinib Should Be Considered as the Preferred First-Line Option in Patients With Advanced ALK-Rearranged NSCLC.

作者信息

Nagasaka Misako, Ou Sai-Hong Ignatius

机构信息

Karmanos Cancer Institute, School of Medicine, Wayne State University, Detroit, Michigan; Division of Neurology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan.

Division of Hematology/Oncology, Department of Medicine, Chao Family Comprehensive Cancer Center, University of California Irvine School of Medicine, Orange, California.